+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032- Product Image
Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888905
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immune Checkpoint Inhibitors Market is projected to reach USD 71.34 Billion in 2026. It is expected to continue growing at a CAGR of 14.41%, reaching USD 160.54 Billion by 2032.

Immune Checkpoint Inhibitors: Executive Overview

Immune checkpoint inhibitors are monoclonal antibody therapies that restore antitumor immune activity by blocking inhibitory pathways such as PD-1, PD-L1, and CTLA-4. Their clinical use has expanded across multiple tumor types, while treatment selection increasingly depends on biomarker status, disease stage, prior therapy, autoimmune risk, and the availability of companion diagnostics. Key strategic issues include evidence generation, safety management, equitable access, and integration with chemotherapy, radiotherapy, targeted therapy, and cellular or other immunotherapies.

Clinical Expansion Is Reshaping Treatment Pathways

The field is shifting from late-line use toward earlier treatment settings, including perioperative and adjuvant approaches in selected cancers. Combination regimens are broadening clinical options but also increase the need for careful patient selection and coordinated toxicity management. Regulatory decisions are increasingly linked to randomized clinical evidence, biomarker-defined populations, overall survival, event-free outcomes, and patient-reported measures. Biosimilar development, contracting pressure, and health-technology assessment are also influencing access and adoption decisions.

Artificial Intelligence Strengthens Selection, Monitoring, and Discovery

Artificial intelligence is being applied to pathology, radiology, genomic interpretation, clinical-trial matching, and prediction of treatment response or immune-related adverse events. Digital tools may help identify subtle tumor and microenvironment features that are not captured by single biomarkers, but their clinical value depends on representative datasets, external validation, interpretability, and workflow integration. Governance remains essential because biased training data, inconsistent laboratory practices, privacy risks, and unsupported algorithmic recommendations could worsen disparities or lead to inappropriate treatment decisions.

Regional Insights: Uneven Access and Evidence Adoption

North America continues to emphasize biomarker-guided treatment, broad oncology infrastructure, and rapid translation of clinical evidence, while reimbursement and affordability remain important considerations. Europe combines strong regulatory and health-technology-assessment systems with variation in national funding, diagnostic access, and treatment sequencing. Asia-Pacific is marked by advanced oncology capabilities in countries such as Japan, South Korea, and Australia alongside substantial differences in availability across markets. Latin America faces uneven diagnostic capacity, public-sector budget constraints, and geographic access barriers. The Middle East is expanding specialized cancer services, with GCC systems generally better positioned for advanced therapies than lower-resource settings. Africa continues to confront limited pathology, oncology workforce, infusion capacity, and medicine access, making scalable delivery models particularly important.

Group Insights: Policy Blocs Shape Access and Standards

ASEAN markets show considerable variation in regulatory maturity, public coverage, diagnostic infrastructure, and dependence on imported medicines. BRICS members combine large and diverse patient populations with differing approaches to domestic production, procurement, clinical research, and reimbursement. The European Union benefits from coordinated regulatory structures but retains national differences in health-technology assessment and funding. G7 countries generally have mature oncology ecosystems, although affordability, waiting times, and regional inequities remain relevant. GCC states are investing in specialized care and precision oncology, while procurement coordination and workforce development influence implementation. NATO members span highly heterogeneous health systems, so shared research capacity does not eliminate differences in access or clinical practice.

Country Insights Across Established and Developing Oncology Systems

The United States combines extensive clinical-trial activity with broad use of biomarker testing, but payer complexity and treatment affordability affect access. Canada has strong academic oncology capacity alongside provincial variation in funding and availability. Mexico and Brazil continue to manage disparities between private and public care, diagnostic capacity, and geographic reach. The United Kingdom emphasizes evidence-based commissioning and national guidance, while France, Germany, Italy, and Spain differ in reimbursement pathways, hospital organization, and regional implementation. Australia supports advanced cancer care through centralized evidence processes, with rural access remaining important. China is expanding domestic oncology innovation and diagnostic capacity, while regional and socioeconomic variation persists. Japan and South Korea have sophisticated healthcare systems and growing precision-oncology capabilities. India faces major differences between metropolitan and rural care, with affordability and pathology access central to uptake. Russia’s access is shaped by public procurement, domestic production priorities, and regional healthcare variation.

Priorities for Leaders: Evidence, Access, and Safe Delivery

Industry leaders should prioritize clinically meaningful evidence that clarifies patient selection, sequencing, combination value, and long-term safety. Companion-diagnostic strategies should be developed alongside therapies, with attention to laboratory quality, turnaround time, and affordability. Organizations should build multidisciplinary pathways for recognizing and managing immune-related adverse events, including primary-care and emergency-care education. Access plans should reflect public and private reimbursement, local procurement, cold-chain and infusion requirements, and rural delivery constraints. Responsible AI programs should use transparent validation, post-deployment monitoring, cybersecurity controls, and human oversight. Partnerships with health systems, patient groups, diagnostic providers, and local research institutions can improve implementation while generating evidence that is relevant to diverse populations.

Methodology: Evidence-Based Review of the Immune Checkpoint Inhibitor Landscape

This executive summary uses a structured qualitative review of publicly available clinical, regulatory, health-policy, and scientific evidence relevant to immune checkpoint inhibitors. The assessment considers mechanism of action, approved and investigational treatment settings, biomarker practices, safety management, diagnostic infrastructure, reimbursement conditions, artificial-intelligence applications, and healthcare-system characteristics. Findings are synthesized across North America, Latin America, Europe, the Middle East, Africa, and Asia-Pacific, and across the specified country and multinational groupings. Claims are limited to verifiable, non-company-specific observations; no market estimates, market shares, or forecasts are presented.

Conclusion: Sustainable Progress Requires Precision and Equity

Immune checkpoint inhibitors have become an important component of modern oncology, but further progress depends on more than expanding indications. Durable value will require reliable biomarkers, evidence-based combinations, proactive toxicity management, responsible use of artificial intelligence, and health systems capable of delivering diagnostics and follow-up care. Regional and country differences in funding, infrastructure, workforce, and regulation mean that access strategies must be locally adapted. Leaders that align clinical innovation with affordability, implementation quality, and transparent evidence will be best positioned to improve outcomes responsibly.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immune Checkpoint Inhibitors Market, by Checkpoint Target
7.1. Introduction
7.2. PD-1
7.3. PD-L1
7.4. CTLA-4
7.5. LAG-3
8. Immune Checkpoint Inhibitors Market, by Drug Class
8.1. Introduction
8.2. Monoclonal Antibodies
8.3. Bispecific Antibodies
8.4. Fusion Proteins
9. Immune Checkpoint Inhibitors Market, by Cancer Type
9.1. Introduction
9.2. Non-Small Cell Lung Cancer
9.3. Small Cell Lung Cancer
9.4. Melanoma
9.5. Renal Cell Carcinoma
10. Immune Checkpoint Inhibitors Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV)
10.3. Subcutaneous (SC)
11. Immune Checkpoint Inhibitors Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Cancer Centers
11.4. Specialty Clinics
11.5. Research Institutes
12. Immune Checkpoint Inhibitors Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. Europe
12.4. North America
12.5. Latin America
12.6. Africa
12.7. Middle East
13. Immune Checkpoint Inhibitors Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. BRICS
13.5. European Union
13.6. ASEAN
13.7. GCC
14. Immune Checkpoint Inhibitors Market, by Country
14.1. Introduction
14.2. China
14.3. United States
14.4. Japan
14.5. India
14.6. Germany
14.7. United Kingdom
14.8. Australia
14.9. France
14.10. South Korea
14.11. Canada
14.12. Italy
14.13. Brazil
14.14. Mexico
14.15. Russia
14.16. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Akeso, Inc.
16.2. Arcus Biosciences, Inc.
16.3. AstraZeneca PLC
16.4. BeiGene, Ltd.
16.5. BioNTech SE
16.6. Bristol-Myers Squibb Company
16.7. Coherus BioSciences, Inc.
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche Ltd
16.10. GlaxoSmithKline plc
16.11. Innovent Biologics, Inc.
16.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
16.13. MacroGenics, Inc.
16.14. Merck & Co., Inc.
16.15. Novartis AG
16.16. Pfizer Inc.
16.17. Regeneron Pharmaceuticals, Inc.
16.18. Sanofi
16.19. Shanghai Junshi Biosciences Co., Ltd.
16.20. Sorrento Therapeutics, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immune Checkpoint Inhibitors Market, Years Considered for the Study
FIGURE 2. Global Immune Checkpoint Inhibitors Market, Research Design
FIGURE 3. Global Immune Checkpoint Inhibitors Market, Research Framework
FIGURE 4. Global Immune Checkpoint Inhibitors Market, Data Triangulation
FIGURE 5. Global Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2025 vs 2032 (%)
FIGURE 7. Global Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immune Checkpoint Inhibitors Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 9. Global Immune Checkpoint Inhibitors Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2025 vs 2032 (%)
FIGURE 11. Global Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immune Checkpoint Inhibitors Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Immune Checkpoint Inhibitors Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immune Checkpoint Inhibitors Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Immune Checkpoint Inhibitors Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Immune Checkpoint Inhibitors Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Immune Checkpoint Inhibitors Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Immune Checkpoint Inhibitors Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Immune Checkpoint Inhibitors Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immune Checkpoint Inhibitors Market Segmentation & Coverage
TABLE 2. Global Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 4. Global PD-1 Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global PD-1 Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global PD-1 Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global PD-L1 Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global PD-L1 Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global PD-L1 Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global CTLA-4 Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global CTLA-4 Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global CTLA-4 Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global LAG-3 Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global LAG-3 Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global LAG-3 Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 17. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Bispecific Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Bispecific Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Bispecific Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Fusion Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Fusion Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Fusion Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 27. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 40. Global Intravenous (IV) Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Intravenous (IV) Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Intravenous (IV) Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Subcutaneous (SC) Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Subcutaneous (SC) Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Subcutaneous (SC) Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 66. Europe Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Europe Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 68. Europe Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 69. Europe Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 70. Europe Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 71. Europe Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. North America Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. North America Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 74. North America Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 75. North America Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 76. North America Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 77. North America Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Latin America Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Latin America Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 80. Latin America Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 81. Latin America Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 82. Latin America Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 83. Latin America Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. Africa Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Africa Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 86. Africa Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 87. Africa Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 88. Africa Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 89. Africa Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Middle East Immune Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Middle East Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 92. Middle East Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 93. Middle East Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 94. Middle East Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 95. Middle East Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 96. Global Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. NATO Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. NATO Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 99. NATO Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 100. NATO Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 101. NATO Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 102. NATO Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. G7 Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. G7 Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 105. G7 Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 106. G7 Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 107. G7 Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 108. G7 Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 109. BRICS Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. BRICS Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 111. BRICS Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 112. BRICS Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 113. BRICS Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 114. BRICS Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. European Union Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. European Union Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 117. European Union Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 118. European Union Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 119. European Union Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 120. European Union Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. ASEAN Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. ASEAN Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 123. ASEAN Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 124. ASEAN Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 125. ASEAN Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 126. ASEAN Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. GCC Immune Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. GCC Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 129. GCC Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 130. GCC Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 131. GCC Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 132. GCC Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Global Immune Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. China Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 135. China Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 136. China Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 137. China Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 138. China Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 139. China Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. United States Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 141. United States Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 142. United States Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 143. United States Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 144. United States Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 145. United States Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. Japan Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 147. Japan Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 148. Japan Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 149. Japan Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 150. Japan Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 151. Japan Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. India Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 153. India Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 154. India Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 155. India Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 156. India Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 157. India Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Germany Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 159. Germany Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 160. Germany Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 161. Germany Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 162. Germany Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 163. Germany Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. United Kingdom Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 165. United Kingdom Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 166. United Kingdom Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 167. United Kingdom Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 168. United Kingdom Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 169. United Kingdom Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Australia Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 171. Australia Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 172. Australia Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 173. Australia Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 174. Australia Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 175. Australia Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. France Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 177. France Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 178. France Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 179. France Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 180. France Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 181. France Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. South Korea Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 183. South Korea Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 184. South Korea Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 185. South Korea Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 186. South Korea Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 187. South Korea Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Canada Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 189. Canada Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 190. Canada Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 191. Canada Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 192. Canada Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 193. Canada Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Italy Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 195. Italy Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 196. Italy Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 197. Italy Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 198. Italy Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 199. Italy Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Brazil Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 201. Brazil Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 202. Brazil Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 203. Brazil Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 204. Brazil Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 205. Brazil Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Mexico Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 207. Mexico Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 208. Mexico Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 209. Mexico Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 210. Mexico Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 211. Mexico Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Russia Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 213. Russia Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 214. Russia Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 215. Russia Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 216. Russia Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 217. Russia Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. Spain Immune Checkpoint Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 219. Spain Immune Checkpoint Inhibitors Market Size, by Checkpoint Target, 2017-2032 (USD Million)
TABLE 220. Spain Immune Checkpoint Inhibitors Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 221. Spain Immune Checkpoint Inhibitors Market Size, by Cancer Type, 2017-2032 (USD Million)
TABLE 222. Spain Immune Checkpoint Inhibitors Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 223. Spain Immune Checkpoint Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Global Immune Checkpoint Inhibitors Market Share, by Key Player, 2025
TABLE 225. Global Immune Checkpoint Inhibitors Market, Key Experts

Companies Mentioned

  • Akeso, Inc.
  • Arcus Biosciences, Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Shanghai Junshi Biosciences Co., Ltd.
  • Sorrento Therapeutics, Inc.

Related Topics

Related Reports

Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032 - Product Image

Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • 190 Pages
  • Global
From
Checkpoint Inhibitor Refractory Cancer - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Checkpoint Inhibitor Refractory Cancer - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030 - Product Image

Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030

  • Report
  • 318 Pages
  • Global
From
Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2026-2034 - Product Image

Immune Checkpoint Inhibitors Market Report by Type, Distribution Channel, Application, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From

About the Immune Checkpoint Inhibitor Market

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.